Evidence map›Paper›PMID 38876307›Full record

ArticleThe Journal of biological chemistry2024

Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors.

Andrew C Goodrich, Norbert P LeClair, Nita Shillova, William D Morton, Arthur J Wittwer, Kelly M Loyet, Rami N Hannoush

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew C GoodrichDepartment of Early Discovery Biochemistry, Genentech, South San Francisco, California, USA. Electronic address: agoodri6@gmail.com.
Norbert P LeClairDepartment of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
Nita ShillovaDepartment of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
William D MortonDepartment of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
Arthur J WittwerDepartment of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
Kelly M LoyetDepartment of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
Rami N HannoushDepartment of Early Discovery Biochemistry, Genentech, South San Francisco, California, USA. Electronic address: ramihannoush@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system plays a critical role in the innate immune response, acting as a first line of defense against invading pathogens. However, dysregulation of the complement system is implicated in the pathogenesis of numerous diseases, ranging from Alzheimer's to age-related macular degeneration and rare blood disorders. As such, complement inhibitors have enormous potential to alleviate disease burden. While a few complement inhibitors are in clinical use, there is still a significant unmet medical need for the discovery and development of novel inhibitors to treat patients suffering from disorders of the complement system. A key hurdle in the development of complement inhibitors has been the determination of their mechanism of action. Progression along the complement cascade involves the formation of numerous multimeric protein complexes, creating the potential for inhibitors to act at multiple nodes in the pathway. This is especially true for molecules that target the central component C3 and its fragment C3b, which serve a dual role as a substrate for the C3 convertases and as a scaffolding protein in both the C3 and C5 convertases. Here, we report a step-by-step in vitro reconstitution of the complement alternative pathway using bio-layer interferometry. By physically uncoupling each step in the pathway, we were able to determine the kinetic signature of inhibitors that act at single steps in the pathway and delineate the full mechanism of action of known and novel C3 inhibitors. The method could have utility in drug discovery and further elucidating the biochemistry of the complement system.

Indexed as

Complement Pathway, AlternativeComplement C3Complement C3bComplement Inactivating AgentsHumansComplement C3Complement C3bComplement Inactivating AgentsBiochemical reconstitutionbio-layer interferometrycomplementdrug discoverydrug screeninginhibition mechanismKineticsprotein–protein interactions

Identifiers

PMID38876307
PMCPMC11283208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.